Skip to content

Pilot study of efficacy of anakinra in acute gouty arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10862635
Enrollment
10
Registered
2007-01-04
Start date
2006-12-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute gout Musculoskeletal Diseases Acute gout

Interventions

Treatment with 100 mg anakinra daily subcutaneously for three days

Sponsors

University Hospital Complex of Vaud (Centre Hospitalier Universitaire Vaudois [CHUV]) (Switzerland)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Acute gout as defined by American College of Rheumatology (ACR) criteria 2. Acute arthritis due to gout which is unresponsive to conventional therapy with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), colchicine or steroids 3. Patients with acute gout who have had side effects or intolerance to either NSAIDs, colchicine or steroids

Exclusion criteria

Exclusion criteria: 1. Patients with on-going or untreated infectious diseases 2. Patients with rheumatoid arthritis, lupus or vasculitis 3. Patients concurrently treated with anti-Tumour Necrotising Factor (TNF) therapies 4. Patients with active cancer

Design outcomes

Primary

MeasureTime frame
1. Pain of arthritis 2. Signs of arthritis

Secondary

MeasureTime frame
Biological markers of inflammation

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 8, 2026